trial

Effects of Intranasal Oxytocin on Satiety Signaling in People With Schizophrenia

NCTId NCT01614093
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 24 (actual)
Sponsored by University of Maryland, Baltimore County
Primary completion 2014-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
24 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Quadruple
Start
2012-06
Primary completion
2014-01
Eligibility
ALL · 18 Years · 54 Years

Interventions & indications

Drugs
Oxytocin

Sponsors

University of Maryland, Baltimore CountyLead Sponsor

Investigators

1
Kimberly Warren, PhDPrincipal Investigator

Sites

1 total
Catonsville, United States

Facts & assertions

4 sourced
Enrollment
24
Phase
PHASE4
Primary Completion Date
2014-01
Status
COMPLETED
relationships
The graph out of here
drug
Oxytocin
drug
lead_sponsor
University of Maryland, Baltimore County
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Kimberly Warren, PhD
person